STOCK TITAN

NewGenIvf Group Limited Announces Pricing of $2.5 Million Underwritten Offering

(Very High)

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Tags

NewGenIvf Group (Nasdaq: NIVF) priced a firm commitment underwritten offering with expected gross proceeds of approximately $2.5 million before fees and expenses.

The offering covers 71,428,570 Class A ordinary shares or pre-funded warrants in their place. Shares are priced at $0.035 per share; the immediately exercisable warrants cost $0.03499 each, with a $0.00001 exercise price. The company expects the offering to close on or about November 20, 2026, subject to customary closing conditions. It expects to use the net proceeds, together with existing cash, for working capital and general corporate purposes.

Loading...
Loading translation...
1 point · 1 major

How this balance works

Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.

It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.

Rhea-AI Sentiment measures something else, the tone of the wording.

1 major · 2 points

Hollow bars mark forward-looking points. How the balance works

Positive

  • Major point. Forward-looking: it has not happened yet and may not happen.Firm commitment underwritten offering is expected to raise approximately $2.5 million in gross proceeds, with closing expected on or about November 20, 2026 9.2× market cap

Negative

  • Major point. Forward-looking: it has not happened yet and may not happen.71,428,570 Class A ordinary shares or pre-funded warrants in their place would dilute existing holders; shares cost $0.035 and warrants cost $0.03499 with a $0.00001 exercise price
  • Minor point. Forward-looking: it has not happened yet and may not happen.Underwriting fees and other offering expenses payable by NewGenIvf Group will reduce net proceeds
Argus 15 min delay 46 alerts
-59.71% vs previous close $0.0687 last price 17.6x rel. volume Open Argus
Details

Market move: NIVF -59.71% vs previous close. $2.5 million underwritten offering

-75.4% Trough in 12 min
$0.06 – $0.18 Day Range
$109,798 Mkt Cap at Last Price

On Nov 19, the day this news came out, the latest delayed price for NIVF is 59.71% below the previous close. Argus tracked a trough of -75.4% from its starting point during tracking. Our momentum scanner has recorded 46 alerts for this stock so far that day. The latest delayed price is $0.07. Relative volume is exceptionally heavy at 17.6x what this stock usually trades by this time of day.

Data tracked by StockTitan Argus (15 min delayed). Upgrade to Gold for real-time data.

Key Figures

Expected gross proceeds: Approximately $2.5 million Offering securities: 71,428,570 Class A ordinary shares Ordinary share price: $0.035 per share +3 more
Expected gross proceeds
Approximately $2.5 million
Before underwriting fees and other offering expenses
Offering securities
71,428,570 Class A ordinary shares
Pre-funded warrants may be issued in lieu of shares
Ordinary share price
$0.035 per share
Offering price
Pre-funded warrant price
$0.03499 per warrant
Offering price
Warrant exercise price
$0.00001 per warrant
Pre-funded warrants
Expected closing
On or about November 20, 2026
Subject to customary closing conditions

Previous Offering Reports

2 past events · Latest: Sep 30
Same Type 2 events
  1. Sep 30

    Offering closing

    24h Move
    +133.3%

    Closed a public offering, raising approximately $1.25 million in gross proceeds.

  2. Sep 28

    Offering pricing

    24h Move
    -79.1%

    Priced a public offering expected to raise approximately $1.25 million in gross proceeds.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

firm commitment, underwritten offering, pre-funded warrants, shelf registration statement, +2 more
6 terms
firm commitment financial
"pricing of a firm commitment underwritten offering"
An underwriting agreement where an investment bank guarantees to buy an entire new issue of securities from an issuer and then resell them to the public. Think of it as a store owner agreeing to buy a whole shipment upfront so the seller gets paid immediately; for investors this matters because it reduces the risk that the offering will fail, sets the initial supply and price pressure in the market, and signals underwriter confidence in selling the shares.
underwritten offering financial
"a firm commitment underwritten offering"
An underwritten offering is when a bank or group of banks agrees to buy all of a company's new shares or bonds and then resell them to outside investors, guaranteeing the company will raise a specific amount of money. It matters to investors because it adds certainty that the funding will close while increasing the number of shares or debt in the market, which can lower the price per share and change each existing owner's ownership percentage—think of a wholesaler buying an entire shipment from a maker before it reaches stores.
pre-funded warrants financial
"or Pre-Funded Warrants in lieu thereof"
Pre-funded warrants are financial instruments that give investors the right to purchase a company's stock at a set price, but with most or all of the purchase price paid upfront. They function like a coupon or gift card for stock, allowing investors to buy shares later at a fixed price, which can be beneficial if they want to avoid future price increases. This makes them important for investors seeking flexibility and certainty in their investment plans.
shelf registration statement regulatory
"made pursuant to an effective shelf registration statement"
A shelf registration statement is a document a company files with regulators that allows it to sell shares or bonds quickly when it’s a good time to raise money. It’s like having a pre-approved plan ready so the company can act fast without going through lengthy paperwork each time they want to sell, making fundraising more flexible.
form f-3 regulatory
"effective shelf registration statement on Form F-3"
Form F-3 is a U.S. securities filing that lets eligible foreign companies pre-register and then quickly sell shares or other securities to raise money, because they already meet ongoing reporting and size tests. For investors it signals that the company is up-to-date with regulatory disclosure and has an efficient way to issue new securities — similar to a pre-approved credit line — which can mean faster capital raises but also potential dilution of existing holdings.
prospectus supplement regulatory
"A final prospectus supplement and accompanying prospectus"
A prospectus supplement is an additional document provided alongside a company's main offering details, offering updated or extra information about a specific financial product being sold. It helps investors understand the latest terms, risks, and details of the investment, similar to how an update or revision clarifies or expands on original instructions, ensuring they have current and complete information before making a decision.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google

BANGKOK, Nov. 19, 2026 (GLOBE NEWSWIRE) -- NewGenIvf Group Limited (NASDAQ: NIVF) (the “Company”), a technology-driven, diversified growth company, today announced the pricing of a firm commitment underwritten offering with gross proceeds to the Company expected to be approximately $2.5 million, before deducting underwriting fees and other offering expenses payable by the Company.

The offering consists of 71,428,570 Class A Ordinary Shares (or Pre-Funded Warrants in lieu thereof). The offering price per Class A Ordinary Share is $0.035 (or $0.03499 for each Pre-Funded Warrant, which is equal to the offering price per Class A Ordinary Share to be sold in the offering minus an exercise price of $0.00001 per Pre-Funded Warrant). The Pre-Funded Warrants will be immediately exercisable and may be exercised at any time until exercised in full. For each Pre-Funded Warrant sold in the offering, the number of Class A Ordinary Shares in the offering will be decreased on a one-for-one basis.

Aggregate gross proceeds to the Company are expected to be approximately $2.5 million. The transaction is expected to close on or about November 20, 2026, subject to the satisfaction of customary closing conditions. The Company expects to use the net proceeds from the offering, together with its existing cash, for general corporate purposes and working capital.

Aegis Capital Corp. is acting as the sole book-running manager for the offering. Han Kun Law Offices LLP is acting as U.S. counsel to the Company. Kaufman & Canoles, P.C. is acting as U.S. counsel to Aegis Capital Corp.

The offering is being made pursuant to an effective shelf registration statement on Form F-3 (No. 333-299649) previously filed with the U.S. Securities and Exchange Commission (SEC) and declared effective by the SEC on November 12, 2026. A final prospectus supplement and accompanying prospectus describing the terms of the proposed offering will be filed with the SEC and will be available on the SEC’s website located at www.sec.gov. Electronic copies of the final prospectus supplement and the accompanying prospectus may be obtained, when available, by contacting Aegis Capital Corp., Attention: Syndicate Department, 1345 Avenue of the Americas, 27th floor, New York, NY 10105, by email at syndicate@aegiscap.com, or by telephone at +1 (212) 813-1010.

Interested parties should read in their entirety the prospectus supplement and the accompanying prospectus and the other documents that the Company has filed with the SEC that are incorporated by reference in such prospectus supplement and the accompanying prospectus, which provide more information about the Company and such offering.

This press release shall not constitute an offer to sell or a solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

About NewGenIvf Group Limited

NewGenIvf Group Limited is a technology-forward, diversified growth company pursuing opportunities across real estate development, digital asset innovation, and reproductive health solutions. The Company operates through NewGenProperty, focused on real estate development projects in Ras Al Khaimah, United Arab Emirates; NewGenDigital, focused on digital asset and decentralized-finance solutions; and NewGenSup, focused on health and longevity products and solutions. NewGenIVF’s legacy business includes IVF and assisted reproductive treatment services across Asia. To learn more, visit www.nivf.global. Information contained on, or accessible through, the Company’s website is not incorporated by reference into this press release.

Forward-Looking Statements

The foregoing material may contain “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, each as amended. Forward-looking statements include all statements that do not relate solely to historical or current facts, including without limitation statements regarding the Company’s product development and business prospects, and can be identified by the use of words such as “may,” “will,” “expect,” “project,” “estimate,” “anticipate,” “plan,” “believe,” “potential,” “should,” “continue” or the negative versions of those words or other comparable words. Forward-looking statements are not guarantees of future actions or performance. These forward-looking statements are based on information currently available to the Company and its current plans or expectations and are subject to a number of risks and uncertainties that could significantly affect current plans. Should one or more of these risks or uncertainties materialize, or the underlying assumptions prove incorrect, actual results may differ significantly from those anticipated, believed, estimated, expected, intended, or planned. Although the Company believes that the expectations reflected in the forward-looking statements are reasonable, the Company cannot guarantee future results, performance, or achievements. Except as required by applicable law, including the securities laws of the United States, the Company does not intend to update any of the forward-looking statements to conform these statements to actual results.

ICR, LLC
Robin Yang
Phone: +1 (212) 537-4406
Email: Newgenivf.IR@icrinc.com


FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How much does NewGenIvf Group expect to raise, and when will the offering close?

NewGenIvf Group expects approximately $2.5 million in gross proceeds before underwriting fees and other offering expenses, with closing expected on or about November 20, 2026, subject to customary closing conditions.

How do the pre-funded warrants work in NewGenIvf Group's offering?

Each pre-funded warrant sold replaces one Class A ordinary share in the offering. A warrant costs $0.03499 and has a $0.00001 exercise price, compared with $0.035 for a share. The warrants are immediately exercisable and can be exercised at any time until exercised in full.

Keep reading